|Bid||14.19 x 3200|
|Ask||14.20 x 900|
|Day's Range||14.14 - 14.57|
|52 Week Range||13.07 - 20.54|
|Beta (3Y Monthly)||0.52|
|PE Ratio (TTM)||3.98|
|Earnings Date||Jul 24, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||15.00|
Innoviva (INVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Innoviva Inc NASDAQ/NGS:INVAView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate Bearish sentimentShort interest | NeutralShort interest is moderate for INVA with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding INVA are favorable, with net inflows of $3.54 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
The company, along with co-developer Innoviva Inc, said the once-daily inhaler improved lung function in patients with uncontrolled asthma, compared to its other medicine Relvar/Breo Ellipta. The results come at a time when GSK is hit by generic competition for its blockbuster asthma treatment Advair and it looks to newer respiratory drugs to make up for declines in older medicines.
GlaxoSmithKline plc and Innoviva, Inc. today announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple therapy Trelegy Ellipta compared to Relvar/Breo Ellipta , in the treatment of patients living with uncontrolled asthma.
The Brisbane, California-based company said it had net income of 31 cents per share. The biopharmaceutical company posted revenue of $55.2 million in the period. Innoviva shares have decreased 20% since ...
BRISBANE, Calif.-- -- Total net revenue increased by 5% to $55.2 million in the first quarter of 2019, compared to the same quarter in 2018. Income before income taxes increased by 60% to $48.5 million in the first quarter of 2019, compared to the same quarter in 2018. Innoviva, Inc. today reported financial results for the first quarter ended March 31, 2019. Gross royalty revenues of $58.6 million ...
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But every investor is virtually certain to have both over-performing and under-performing stocks...
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also plenty of examples of share prices declining precipitously after insidersRead More...
Innoviva Inc (NASDAQ:INVA) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
Announcement: Moody's announces completion of a periodic review of ratings of Innoviva, Inc. New York, February 15, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Innoviva, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
On a per-share basis, the Brisbane, California-based company said it had profit of $2.34. The biopharmaceutical company posted revenue of $79.9 million in the period. For the year, the company reported ...
BRISBANE, Calif.-- -- Total net revenue rose 15% to $79.9 million in the fourth quarter of 2018 compared with the fourth quarter of 2017. 1 Income before income taxes increased 25% from the fourth quarter of 2017 to $73.1 million. Innoviva, Inc. today reported financial results for the fourth quarter ended December 31, 2018. Gross royalty revenues of $83.3 million from Glaxo Group Limited for the fourth ...
NEW YORK, Feb. 06, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Mylan stock popped late Wednesday after the Food and Drug Administration approved its generic version of GlaxoSmithKline asthma inhaler Advair. Mylan shares rose 7%.